Back to results
US 2021/0069152 A1Published application
Methods for treating heterotopic ossification
AssigneeClementia Pharmaceuticals Inc.
InventorsClarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
Life of this patent
Estimating the term…
Abstract
The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Claims18
A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, said method comprising during a period when the subject is experiencing at least one flare-up symptom:
- (i) orally administering to the subject an amount of 20±1.0 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 20 to 40 days, and (ii) after the period of 20 to 40 days, orally administering to the subject an amount of 10±1.0 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 14 to 112 days.
Dependencies are inferred from the claim text.